Thursday, 24 September 2020

Opening Plenary
09:00 - 10:00

S01, Opening Symposium

Objectives:
At the end of the session, the participant will be able to

- Get an overview of the different ECFS projects to improve cystic fibrosis care, education and research
- Describe the epidemiology of COVID-19 in patients with cystic fibrosis in Europe
- Discuss the future care of patients with cystic fibrosis

Isabelle Fajac (Paris, France)

ECFS President address

Isabelle Fajac (Paris, France)

09:00 - 09:20

COVID-19 in patients with cystic fibrosis

Lutz Nährlich (Giessen, Germany)

09:20 - 09:40

In the light of the COVID-19 pandemic and in the era of CFTR modulators, what could the future follow-up of patients with cystic fibrosis be like?

Isabelle Durieu (Lyon, France)

09:40 - 10:00

Symposium
10:15 - 11:45

S02, Following treatment outcomes in patients on CFTR modulators

Objectives:
At the end of the session, the participant will be able to

- Discuss the CFTR modulator effects on the gastrointestinal system
- Discuss how to reduce the burden of treatment in patients on CFTR modulators
- Review the effects of lumacaftor/ivacaftor in real life
- Outline the long-term effects of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis

Isabelle Fajac (Paris, France)

CFTR modulator effects on the gastrointestinal system

Keith Chee Y. Ooi (Randwick, Australia)

10:15 - 10:37

A treatment withdrawal trial following CFTR modulator initiation

Gwyneth Davies (London, United Kingdom)

10:37 - 10:59

Real life efficacy of lumacaftor/ivacaftor combination: the French experience

Pierre-Régis Burgel (Paris, France)

10:59 - 11:21
**Scientific Programme**

A phase 3, open-label extension study of elexacaftor/tezacaftor/ivacaftor: interim analysis of safety and efficacy in people with cystic fibrosis and F508del/minimal function or F508del/F508del genotypes  
Matthias Griese (Munich, Germany)

**Satellite Symposium**  
12:45 - 13:45  
Online

The journey ahead: Reimagining the future of cystic fibrosis in an era of precision therapies  
Please find the detailed programme of the Satellite Symposia [here](#).

Isabelle Fajac (Paris, France)

- **Welcome and introduction**  
  Isabelle Fajac (Paris, France)  
  12:45 - 12:50
- **The future of CF in perspective**  
  Isabelle Fajac (Paris, France)  
  12:50 - 12:55
- **The evolving natural history of CF**  
  Ed McKone (Dublin, Ireland)  
  12:55 - 13:05
- **Rethinking care for an ageing community**  
  Barry Plant (Cork, Ireland)  
  13:05 - 13:20
- **A changing landscape in CF: Challenges and opportunities to optimise care provision**  
  Daniel Peckham (Leeds, United Kingdom)  
  13:20 - 13:30
- **Panel discussion and Q&A**  
  Isabelle Fajac (Paris, France)  
  13:30 - 13:45

**Symposium**  
14:15 - 15:45  
Online

S03, The future of clinical research

**Objectives:**  
At the end of the session, the participant will be able to

- Outline the requirements and need for new clinical trials in cystic fibrosis
- Provide a detailed understanding of how we can measure the clinical and laboratory impact of CFTR modulators
- Explore the impact and direction of clinical trials networks in cystic fibrosis

Carsten Schwarz (Berlin, Germany)

- **How do we design new clinical trials**  
  Kris De Boeck (Leuven, Belgium)  
  14:15 - 14:37
Scientific Programme

The biomarker response to CFTR modulation
Isabelle Sermet-Gaudelus (Paris, France) 14:37 - 14:59

How can we measure the impact of new CFTR modulators
Paul McNally (Dublin, Ireland) 14:59 - 15:21

What is the future of clinical trial networks
George Retsch-Bogart (Chapel Hill, United States) 15:21 - 15:45

Symposium
16:00 - 17:30
Online

S04, Non-Pseudomonas aeruginosa pathogens in cystic fibrosis

Objectives:
At the end of the session, the participant will be able to

- Discuss the changes of the microbial epidemiology on a large scale using the European Registry
- Outline the clinical impact of respiratory viruses in patients with cystic fibrosis
- Discuss whether or not first detection of Mycobacterium abscessus should be followed by eradication programs

Michael Tunney (Belfast, United Kingdom)

Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis: data from the European Registry 16:00 - 16:22
Elpis Hatziagorou (Thessaloniki, Greece)

Significance of non-P. aeruginosa Gram-negative infection in CF 16:22 - 16:44
Andrew Jones (Manchester, United Kingdom)

People with CF should be offered eradication treatment following a first growth of Mycobacterium abscessus - PRO 16:44 - 17:02
Tavs Qvist (Copenhagen, Denmark)

People with CF should be offered eradication treatment following a first growth of Mycobacterium abscessus - CON 17:02 - 17:20
Charles Haworth (Cambridge, United Kingdom)

Discussion 17:20 - 17:30

Satellite Symposium
17:45 - 18:45
Online

Cystic fibrosis multidisciplinary care: a holistic approach

Introduction 17:45 - 17:50
Nichola McDuff (Wolverhampton, United Kingdom)

The clinical perspective of today’s CF care modalities 17:50 - 18:00
Benedetta Fabrizzi (Ancona, Italy)
Scientific Programme

**The broadened role of physiotherapy in today’s CF management**
Hugues Gauchez (Lille, France)  
18:00 - 18:10

**Medical care and the patient, beyond the treating physician**
Nichola McDuff (Wolverhampton, United Kingdom)  
18:10 - 18:20

**A patient’s view of current and future needs in cystic fibrosis care**
Tim Wotton (Wimbledon, United Kingdom)  
18:20 - 18:30

**Q&A & Close**
Nichola MacDuff (Wolverhampton, United Kingdom)  
18:30 - 18:45
**Satellite Symposium**
**07:45 - 08:45**
**Online**

**Current & future strategies in an evolving cystic fibrosis treatment landscape**

Isabelle Sermet-Gaudelus (Paris, France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45 - 07:50</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>Isabelle Sermet-Gaudelus (Paris, France)</td>
</tr>
<tr>
<td>07:50 - 08:03</td>
<td><strong>Real-life approaches to managing P. aeruginosa infections in cystic fibrosis</strong></td>
</tr>
<tr>
<td></td>
<td>Carsten Schwarz (Berlin, Germany)</td>
</tr>
<tr>
<td>08:03 - 08:16</td>
<td><strong>The future of antibiotics in an era of new therapies in cystic fibrosis</strong></td>
</tr>
<tr>
<td></td>
<td>Barry Plant (Cork, Ireland)</td>
</tr>
<tr>
<td>08:16 - 08:29</td>
<td><strong>In the future, what approaches can be used to address treatment burden in cystic fibrosis?</strong></td>
</tr>
<tr>
<td></td>
<td>Christophe Marguet (Rouen, France)</td>
</tr>
<tr>
<td>08:29 - 08:45</td>
<td><strong>Q&amp;A and Closing Remarks</strong></td>
</tr>
</tbody>
</table>

**Symposium**
**09:00 - 10:30**
**Online**

**S05, New challenges for diagnosis in cystic fibrosis, from pregnancy to adulthood**

Objectives:
At the end of the session, the participant will be able to

- Discuss insight concerning the clarification of diagnosis after a non-conclusive diagnosis at screening
- Discuss the future challenges of cystic fibrosis newborn screening
- Describe new cystic fibrosis diagnostic tools such as non-invasive prenatal diagnosis or new sweat test techniques

Isabelle Sermet-Gaudelus (Paris, France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:22</td>
<td><strong>Challenges ahead of newborn screening in Europe</strong></td>
</tr>
<tr>
<td></td>
<td>Kevin Southern (Liverpool, United Kingdom)</td>
</tr>
<tr>
<td>09:22 - 09:44</td>
<td><strong>Non-concluded diagnosis after neonatal screening: how to clarify the diagnosis?</strong></td>
</tr>
<tr>
<td></td>
<td>Mieke Boon (Leuven, Belgium)</td>
</tr>
<tr>
<td>09:44 - 10:06</td>
<td><strong>Non-invasive prenatal diagnosis of cystic fibrosis: a new option for parents</strong></td>
</tr>
<tr>
<td></td>
<td>Juliette Nectoux (Paris, France)</td>
</tr>
<tr>
<td>10:06 - 10:30</td>
<td><strong>The new sweat tests</strong></td>
</tr>
<tr>
<td></td>
<td>Marco Zampoli (Cape Town, South Africa)</td>
</tr>
</tbody>
</table>
Scientific Programme

Symposium
11:00 - 12:30

S06, Body and Soul – Psychological influences on physical outcomes

Objectives:
At the end of the session, the participant will be able to

- Describe the emotional processes generated by Covid-19 pandemic in people with cystic fibrosis
- Discuss how psychological processes influence people’s choices to take treatment.
- Understand the role of psychology in pain and how psychological interventions can help in the management of pain
- Outline the challenges of respiratory physiotherapy in people with Covid-19 and cystic fibrosis

Mandy Byron (London, United Kingdom)

The emotional impact of Covid-19 on people with CF and their families; current understanding
Trudy Havermans (Leuven, Belgium)

Treating anxiety and health fears to improve adherence to treatment
Urszula Borawska-Kowalczyk (Warsaw, Poland)

Changing the perception of pain: How cognitive behaviour therapy improves management of pain in cystic fibrosis
Marieke Verkleij (Amsterdam, Netherlands)

A case presentation: Anxiety caused by a global pandemic and its effect on physiotherapy management
Sarah Fitzgerald (London, United Kingdom)

Satellite Symposium
12:45 - 13:45

The importance of inhaled antibiotics in the age of disease modifiers

Please find the detailed programme of the Satellite Symposia here.

Daniel Peckham (Leeds, United Kingdom)

Welcome and introductions
Daniel Peckham (Leeds, United Kingdom)

Changes in microbiology and treatment after the introduction of CFTR modulators
Harry Heijerman (Utrecht, Netherlands)

The role of inhaled antibiotics in cystic fibrosis
Daniel Peckham (Leeds, United Kingdom)

Q&A, summary and meeting close
Daniel Peckham (Leeds, United Kingdom)
Scientific Programme

Symposium
14:00 - 15:30

S07, From disease mechanisms to novel therapies

Objectives:
At the end of the session, the participant will be able to

- Understand how complex alleles impact on cystic fibrosis disease as well as their effect on responses to current CFTR modulator treatment
- Discuss the progress in the development of primary cell cultures into 3D patient-derived disease models, which will enable precision treatment of cystic fibrosis
- Discuss the rationale to target non-CFTR ion transport channels in airway epithelia
- Appreciate how directly targeting mucin polymer structure and interactions might alleviate mucus obstruction of cystic fibrosis airways

Carlos M Farinha (Lisbon, Portugal)

CFTR modulators in the context of CFTR complex alleles 14:00 - 14:22
Alexandre Hinzpeter (Paris, France)

Primary cells as tools for precision therapy 14:22 - 14:44
Jeffrey Beekman (Utrecht, Netherlands)

TMEM16A, an alternative pathway to Cl- secretion? 14:44 - 15:06
Henry Danahay (Brighton, United Kingdom)

A glycopolymer that alters mucus properties and improves mucociliary clearance in cystic fibrosis 15:06 - 15:30
Steven M. Rowe (Birmingham, United States)

Symposium
16:00 - 17:30

S08, Updates for the gut and the pancreas

Objectives:
At the end of the session, the participant will be able to

- Outline which factors need to be taken into account when researching the gut microbiome
- Discuss if the dietary focus needs to change from a calorie-dense diet towards a diet promoting certain microbiotic strains
- Review the pancreatic disease in cystic fibrosis
- Discuss the influence of CFTR dysfunction in CFTR-related diabetes with regard to overall suspected pathophysiology.

Carlo Castellani (Genoa, Italy)

The gut microbiome- what has to be taken into consideration for cystic fibrosis? 16:00 - 16:22
Sébastien Boutin (Heidelberg, Germany)

Can we reinforce the cavalry? 16:22 - 16:44
Stephanie Van Biervliet (Ghent, Belgium)
Scientific Programme

**Pancreatic disease in cystic fibrosis: an overview**  
16:44 - 17:06  
Jay Freeman (Atlanta, United States)

**Is Cystic Fibrosis Related Diabetes related to CFTR dysfunction?**  
17:06 - 17:30  
Remi Rabasa-Lhoret (Montréal, Canada)

Satellite Symposium  
17:45 - 18:45  
Online

**Completing the journey for all patients**

Please find the detailed programme of the Satellite Symposia [here](#).

Marcus Mall (Berlin, Germany)

- **Welcome and introduction**  
  17:45 - 17:50  
  Marcus Mall (Berlin, Germany)

- **Completing the picture in cystic fibrosis (CF): challenges and opportunities**  
  17:50 - 18:00  
  Marcus Mall (Berlin, Germany)

- **Tuning in to the right channel - what have we learnt from CFTR?**  
  18:00 - 18:15  
  Paul Negulescu (San Diego, United States)

- **Beyond F508del: getting to all CF mutations**  
  18:15 - 18:30  
  Fredrick Van Goor (San Diego, United States)

- **Panel discussion and Q&A**  
  18:30 - 18:45  
  Marcus Mall (Berlin, Germany)